Mixed Lineage Kinase
抑制剂选择性比较
Mixed Lineage Kinase产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7343 |
URMC-099URMC-099是一种口服生物有效的，大脑渗透性mixed lineage kinase (MLK)抑制剂，对MLK1, MLK2, MLK3,和DLK的IC50分别为19 nM, 42 nM, 14 nM,以及150 nM，也能抑制LRRK2的活性，IC50为11 nM。 |
||
| S8251 |
NecrosulfonamideNecrosulfonamide是一种特异的、有效的细胞坏死抑制剂，通过抑制MLKL发挥其作用。 |
Necroptotic death of HT-29 cells was verified using RIP1 or MLKL inhibitors necrostatine-1 and necrosulfonamide. HT-29 were pre-treated with the combinations of 10 nM birinapant, 50 μM z-VAD, 50 μM necrostatin and 20 μM necrosulfonamide as shown for 1 h, and then treated with 100 ng/ml of TST-TRAIL-wt, 4.2, 5.1 and 5.2 for 8 h.
|
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7343 |
URMC-099URMC-099是一种口服生物有效的，大脑渗透性mixed lineage kinase (MLK)抑制剂，对MLK1, MLK2, MLK3,和DLK的IC50分别为19 nM, 42 nM, 14 nM,以及150 nM，也能抑制LRRK2的活性，IC50为11 nM。 |
||
| S8251 |
NecrosulfonamideNecrosulfonamide是一种特异的、有效的细胞坏死抑制剂，通过抑制MLKL发挥其作用。 |
Necroptotic death of HT-29 cells was verified using RIP1 or MLKL inhibitors necrostatine-1 and necrosulfonamide. HT-29 were pre-treated with the combinations of 10 nM birinapant, 50 μM z-VAD, 50 μM necrostatin and 20 μM necrosulfonamide as shown for 1 h, and then treated with 100 ng/ml of TST-TRAIL-wt, 4.2, 5.1 and 5.2 for 8 h.
|
沪公网安备 31011502012800号